Xolair 150 MG/ML syringeml
Ended Awarded Last action
- Contract number
- SPE2DR26FCFP0
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $27,636
Award facts
- Contract value 100% obligated
- $27,636.35 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $27,636.35 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 150 mg/mL syringes. The award, issued on January 6, 2026, with an ultimate completion date of January 28, 2026, utilizes a firm fixed-price contract structure with no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) established through the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a comprehensive $30.3 billion acquisition strategy designed to consolidate pharmaceutical supply chains across Department of Defense healthcare facilities worldwide.
DMS Pharmaceutical Group has demonstrated substantial performance as a critical pharmaceutical supplier within the federal military medical system since its establishment as a PPV-G GEN V prime vendor in November 2025. The company's product portfolio encompasses a broad range of therapeutic categories including biologics such as Xolair, specialty pharmaceuticals, oncology treatments, vaccines, and medical consumables. Through its role as a regional prime vendor contractor, DMS Pharmaceutical Group is positioned to support recurring medical supply needs of military healthcare facilities globally, leveraging its established capabilities to fulfill the diverse and specialized pharmaceutical requirements of Department of Defense operations.
Quick answers
Who was awarded contract SPE2DR26FCFP0?
SPE2DR26FCFP0 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 6, 2026.
How much is contract SPE2DR26FCFP0 worth?
The government has obligated $27,636 on SPE2DR26FCFP0.
Is contract SPE2DR26FCFP0 an order under another contract?
Yes. SPE2DR26FCFP0 is a delivery order under SPE2DR25D9133, an indefinite delivery contract.
Was contract SPE2DR26FCFP0 competed?
The extent of competition for SPE2DR26FCFP0 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award